Selection of a clinical candidate in the CT-03 project

Current report No. 33/2024

Date of preparation: 23.09.2024

Subject: Selection of a clinical candidate in the CT-03 project

Legal basis: Article 17(1) MAR - confidential information.

The Management Board of Captor Therapeutics S.A. with its registered office in Wrocław (the "Company"), informs that Following successful preclinical studies in crab-eating macaques, the company has nominated a clinical candidate. The results of these studies indicate a wide therapeutic window for the molecule, representing a significant step forward in drug development. The drug candidate being developed under the CT -03 project may be considered “first-in-class" because, to the Company's knowledge, it is the only MCL-1 degrader currently being developed by a pharmaceutical company. Since this approach utilizes degraders, which act differently to inhibitors, and don't cause MCL-1 accumulation, there is a reduced risk of cardiotoxicity, something that have been observed in preclinical models.

Following the selection of the lead drug candidate, Captor has initiated large scale synthesis with a reputable Contract Development and Manufacturing Organization. The company is intensifying its preparations for clinical trials and plans to submit an IND/CTA application by the end of 2025.

The Company will inform about the further course of the proceedings in accordance with the requirements of the law.